$OPK Somatrogon $7 billion global market. Essentially zero cost to OPKO for the cash stream from this business. A very lowball estimate of $500MM annually and PE of 20 places this stock at $10. PLUS all of the additional catalysts mentioned in the report today. SO many investors disappointed stock did not double upon report. Once they sell and leave, the stock will resume its upward trek! GO OPKO! Frost is managing the business for the benefit of long term investors.